Studies how one exercise session affects liver-related proteins in people with liver cancer
Tests a single endurance exercise session in adults with liver cancer.
Plain-language title generated from the registry record
Registry title: Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
Key facts
- Where
- Clermont-Ferrand, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07189624, who can take part
Where in France
- CHU de Clermont-FerrandClermont-Ferrand, FranceTaking people
- Chu Estaing Medecine Digestive Et HepatobiliaireClermont-Ferrand, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT07189624
- Record updated
- 9 November 2026
- Original description
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.Read full original descriptionShow less
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.
Inclusion: Hepatocellular carcinoma developed on cirrhosis; Cirrhosis of any etiology, defined by a liver elasticity measurement >15kPa or a history of cirrhosis decompensation; Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization; Child-Pugh scores A and B7; WHO score ≤ 2; Affiliation to french national social security system.
Exclusion: Surgery performed within 30 days prior to inclusion visit; Liver transplant; Hepatic encephalopathy grade II or higher; Bone metastasis; Muscle injury within 3 months of inclusion; Pregnant or breast-feeding women; Patients under legal protection (guardianship, curatorship, safeguard of justice); Participation in another clinical trial within 10 days of inclusion.